Primer probe combination for detecting human torque teno virus and application thereof
By designing specific primer probe combination and real-time fluorescence quantitative PCR technology, the classification and identification problem of human parvovirus detection in the existing technology is solved, and high-throughput, high sensitivity and high specificity detection is achieved, suitable for clinical use. Applications simplify operational processes and reduce costs.
Patent Information
- Application Number
- CN202411264307.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-10
- Publication Date
- 2024-11-15
AI Technical Summary
The existing detection methods cannot efficiently and accurately classify human parvovirus TTV, TTMV and TTMDV, and there are problems such as long detection time, high cost, insufficient specificity and sensitivity.
Design specific primer probe combinations and adopt real-time fluorescence quantitative PCR technology to provide methods for detecting and identifying human parvoviruses with high throughput, high sensitivity and high specificity, including primer probe combinations and PCR kits for different viruses , simplify the operation process and directly implement detection on a fully automatic platform.
It realizes efficient and accurate typing and identification of TTV, TTMV and TTMDV, reduces detection time and cost, improves the reliability and specificity of the detection results, and is suitable for clinical applications.
Smart Images

Figure BDA0005036704510000051 
Figure BDA0005036704510000061 
Figure BDA0005036704510000062
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of molecular biology, in particular to a primer-probe combination for detecting human parvovirus and an application thereof. Background Art
[0002] Anellovirus (AV) is a single-stranded, negative-stranded, circular, non-enveloped DNA virus that can infect different parts of the body and cause different clinical symptoms. According to the International Committee on Taxonomy of Viruses (ICTV), the Anelloviridae family contains 30 identified genera, including three common species of cycloviruses that infect humans, namely, Torque tenovirus (TTV) of the Alphatorquevirus genus, Torque teno minivirus (TTMV) of the Betatorquevirus genus, and Torque teno midivirus (TTMDV) of the Gammatorquevirus genus.
[0003] The size of human cyclovirus is 2.8 to 3.9 kb, including an untranslated region (UTR) of about 1.2 kb and a coding region of about 2.6 kb. The sequence of the non-coding region is conserved and is related to viral replication. The coding region contains two major open reading frames, ORF1 and ORF2, which encode viral capsid proteins related to viral replication. Cyclovirus is ubiquitous and may be associated with a variety of clinical symptoms. Any biological individual carrying cyclovirus is a source of infection. According to current reports, there is a high probability that cyclovirus will be detected in healthy people. Cyclovirus is related to the human immune system and may have a pathogenic effect on immunocompromised people. In addition, the cyclovirus load can be used as an indicator to predict allogeneic rejection and infection risk in renal transplant recipients.
[0004] Human parvovirus is poorly conservative, with few identification techniques and a lack of in-depth research. Common detection methods include serological testing, polymerase chain reaction (PCR) and second-generation sequencing technology, and different methods vary greatly. Serological methods mainly detect viral antibodies and corresponding antigens, with a long detection cycle, cumbersome operation steps, and relatively poor specificity and sensitivity. Second-generation sequencing is a novel high-throughput sequencing technology used in genomic research. It has the characteristics of high throughput and high sensitivity and has been applied to the field of virus detection, but its detection time is long and the cost is high. The polymerase chain reaction greatly makes up for the limitation of high requirements for sample nucleic acid concentration, and has the characteristics of high detection sensitivity and good specificity, but the conventional PCR method usually cannot obtain the detection result in one step, and requires gel electrophoresis to assist in judgment. The electrophoresis step not only increases labor costs and detection time, but also easily leads to contamination and produces false positive results.
[0005] Human parvovirus is common in clinical samples of unexplained fever symptoms, and may be mixed with one or more of TTV, TTMV, and TTMDV. Some scholars believe that the pathogenicity of parvovirus is related to its type, so corresponding typing detection methods are needed, but there is currently a lack of accurate technical methods to type and detect these three viruses. Hunan Provincial Institute of Occupational Disease Prevention and Control provides a detection kit for detecting human parvovirus and its application, which only detects TTV virus and cannot type and identify TTV, TTMV and TTMDV. Summary of the invention
[0006] In view of this, the present invention provides a primer-probe combination for detecting human tenovirus and its application. The present invention designs specific primer probes for characteristic genes and adopts real-time fluorescence quantitative PCR technology to provide a primer-probe combination for detecting human tenovirus and an identification method for human tenovirus TTV, TTMV and TTMDV. The identification method of the present invention has the advantages of high throughput, high sensitivity, high specificity, strong random detection, and can better match the advantages of a fully automatic platform, providing an efficient solution for in vitro qualitative identification of human tenovirus TTV, TTMV and TTMDV, and has important clinical significance.
[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0008] The present invention provides a primer-probe combination for detecting human parvovirus, including any one of three primer-probe combinations:
[0009] The first set of primer-probe combinations includes: a first primer pair for specifically amplifying the 5'UTR gene of TTV; and a first probe for detecting the amplification product of the first primer pair;
[0010] The second set of primer-probe combinations includes: a second primer pair for specifically amplifying the 5'UTR gene of TTMV; and a second probe for detecting the amplification product of the second primer pair;
[0011] The third set of primer-probe combinations includes: a third primer pair for specifically amplifying the ORF1 gene of TTMDV; and a third probe for detecting the amplification product of the third primer pair.
[0012] Preferably, the region amplified and detected by the first primer pair and the first probe of the present invention is: 111-207 (FR751482);
[0013] The region amplified and detected by the second primer pair and the second probe of the present invention is: 129-285 (MH017559);
[0014] The region amplified and detected by the third primer pair and the third probe of the present invention is: 2718-2804 (MN779906).
[0015] The present invention provides a primer-probe combination for detecting human parvovirus, the primer-probe combination comprising:
[0016] (I), a specific primer pair having the nucleotide sequences shown in SEQ ID NO.1 and SEQ ID NO.2;
[0017] A specific probe having a nucleotide sequence as shown in SEQ ID NO.3; and / or
[0018] (II), a specific primer pair having the nucleotide sequences shown in SEQ ID NO.4 and SEQ ID NO.5;
[0019] A specific probe having a nucleotide sequence as shown in SEQ ID NO.6; and / or
[0020] (III), a specific primer pair having a nucleotide sequence as shown in SEQ ID NO.7, SEQ ID NO.8 and SEQ ID NO.9;
[0021] A specific probe having a nucleotide sequence as shown in SEQ ID NO.10; and / or
[0022] (IV) a nucleotide sequence encoding the same protein as the nucleotide sequence shown in any one of (I) to (III) but different from the nucleotide sequence shown in any one of (I) to (III) due to the degeneracy of the genetic code; or
[0023] (V) a nucleotide sequence obtained by replacing, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in any one of (I) to (IV), and a nucleotide sequence having the same or similar function as the nucleotide sequence shown in any one of (I) to (IV); or
[0024] (VI) A nucleotide sequence having at least 90% sequence homology with the nucleotide sequence of any one of (I) to (V).
[0025] In some specific embodiments of the present invention, the primer-probe combination further comprises a primer pair and a probe for amplifying and detecting an internal reference gene, wherein the internal reference gene comprises one or more of GAPDH, ribonuclease P, β-globin or Actin.
[0026] In some specific embodiments of the present invention, the primer-probe combination further comprises:
[0027] (I), an internal reference primer pair having the nucleotide sequences shown in SEQ ID NO.11 and SEQ ID NO.12;
[0028] A specific probe having a nucleotide sequence as shown in SEQ ID NO.13; or
[0029] (II) a nucleotide sequence that encodes the same protein as the nucleotide sequence shown in (I) but is different from the nucleotide sequence shown in (I) due to the degeneracy of the genetic code; or
[0030] (III) a nucleotide sequence obtained by replacing, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in (I) or (II), and having the same or similar function as the nucleotide sequence shown in (I) or (II); or
[0031] (IV) A nucleotide sequence having at least 90% sequence homology with the nucleotide sequence of any one of (I) to (III).
[0032] In some specific embodiments of the present invention, the primer-probe combination for identifying TTV includes: two primers having nucleotide sequences as shown in SEQ ID NO.1-2, and a probe having a nucleotide sequence as shown in SEQ ID NO.3.
[0033] In some specific embodiments of the present invention, the primer-probe combination for identifying TTMV includes: two primers having nucleotide sequences as shown in SEQ ID NO.4-5, and a probe having a nucleotide sequence as shown in SEQ ID NO.6.
[0034] In some specific embodiments of the present invention, the primer-probe combination for identifying TTMDV includes: three primers having nucleotide sequences as shown in SEQ ID NO.7-9, and a probe having a nucleotide sequence as shown in SEQ ID NO.10.
[0035] In some specific embodiments of the present invention, the primer-probe combination for detecting the internal reference includes: two primers having nucleotide sequences as shown in SEQ ID NOs: 11-12, and a probe having a nucleotide sequence as shown in SEQ ID NO: 13; the internal reference is the β-globin gene.
[0036] In some specific embodiments of the present invention, the probe includes a fluorescent group and a quenching group, and the fluorescent group includes FAM, VIC, ROX, CY5, and JOE.
[0037] The quenching groups include BHQ1, BHQ2, BHQ3, SQ1, and SQ2.
[0038] In some specific embodiments of the present invention, the specific probe having the nucleotide sequence shown in SEQ ID NO.3 includes a FAM group;
[0039] The specific probe having the nucleotide sequence shown in SEQ ID NO.6 includes a ROX group;
[0040] The specific probe having the nucleotide sequence shown in SEQ ID NO.10 includes a CY5 group;
[0041] The specific probe having the nucleotide sequence shown in SEQ ID NO. 13 includes a HEX group.
[0042] In some specific embodiments of the present invention, the 5' end of the specific probe having the nucleotide sequence shown in SEQ ID NO.3 is modified with a FAM group, and the 3' end is modified with a BHQ1 group;
[0043] The 5' end of the specific probe having the nucleotide sequence shown in SEQ ID NO.6 is modified with a ROX group, and the 3' end is modified with a BHQ2 group;
[0044] The 5' end of the specific probe having the nucleotide sequence shown in SEQ ID NO. 10 is modified with a CY5 group, and the 3' end is modified with a BHQ3 group;
[0045] The 5' end of the specific probe having the nucleotide sequence shown in SEQ ID NO. 13 is modified with a HEX group, and the 3' end is modified with a BHQ1 group.
[0046] The present invention also provides the use of the primer-probe combination in preparing a reagent or a kit for detecting and / or identifying human parvovirus.
[0047] In some specific embodiments of the present invention, the human parvovirus includes TTV, TTMV and TTMDV.
[0048] The present invention also provides a combined reagent, comprising the primer-probe combination.
[0049] The present invention also provides a kit, comprising any of the following items and PCR reaction reagents:
[0050] (I), the primer-probe combination; and / or
[0051] (II), the combined reagent.
[0052] In some specific embodiments of the present invention, the PCR reaction reagents include: dNTP, DNA polymerase, buffer, enzyme activator;
[0053] The buffer comprises one or more of Tris-HCl, KCL and glycerol.
[0054] In some specific embodiments of the present invention, the enzyme is a bifunctional DNA polymerase.
[0055] In some specific embodiments of the present invention, the enzyme activator comprises Mn 2+ Mg 2+ At least one of .
[0056] In some specific embodiments of the present invention, the total system may be 30 μL, 50 μL, 80 μL, or 100 μL.
[0057] In some specific embodiments of the present invention, based on a total system of 50 μL, the reaction system of the kit comprises:
[0058]
[0059] In some specific embodiments of the present invention, the kit further comprises a positive quality control and a negative quality control; the positive quality control comprises a TE solution containing TTV plasmid, TTMV plasmid and TTMDV plasmid, and a β-globin gene plasmid; the negative quality control comprises a TE solution containing a human β-globin gene plasmid.
[0060] The PCR reaction procedure includes:
[0061]
[0062] In some specific embodiments of the present invention, the PCR reaction procedure includes:
[0063]
[0064] The present invention also provides a method for identifying human tenoviruses TTV, TTMV and TTMDV, comprising the following steps:
[0065] Step 1, obtaining DNA of the sample to be tested;
[0066] Step 2: Perform PCR amplification on the DNA of the sample to be tested using the kit to obtain a Ct value.
[0067] In some specific embodiments of the present invention, the method for identifying human parvoviruses TTV, TTMV and TTMDV comprises the following steps:
[0068] Step 1, obtaining DNA of the sample to be tested;
[0069] Step 2, using the kit to perform PCR amplification on the DNA of the sample to be tested to obtain a Ct value;
[0070] If the HEX channel Ct value of the DNA of the sample to be tested is >35 or NoCt, the result is invalid;
[0071] If the HEX channel Ct value of the negative control product is ≤35, other channels display NoCt; the HEX channel Ct value of the positive control product is ≤35, and the FAM, ROX, and CY5 channel Ct values are <30; the FAM channel Ct value of the DNA of the sample to be tested is ≤38, TTV is determined to be positive;
[0072] If the HEX channel Ct value of the negative control product is ≤35, other channels display NoCt; if the HEX channel Ct value of the positive control product is ≤35, and the FAM, ROX, and CY5 channel Ct values are <30; if the ROX channel Ct value of the DNA of the sample to be tested is ≤38, TTMV is determined to be positive;
[0073] If the HEX channel Ct value of the negative control product is ≤35, other channels display No Ct; the HEX channel Ct value of the positive control product is ≤35, and the FAM, ROX, and CY5 channel Ct values are <30; the CY5 channel Ct value of the DNA of the sample to be tested is ≤38, TTMDV is determined to be positive.
[0074] In some embodiments of the invention, the identification method is used for non-disease diagnosis purposes.
[0075] The present invention also provides a method for detecting human parvoviruses TTV, TTMV and TTMDV, comprising the following steps:
[0076] Step 1, obtaining DNA of the sample to be tested;
[0077] Step 2, using the kit to perform PCR amplification on the DNA of the sample to be tested to obtain a Ct value;
[0078] If the HEX channel Ct value of the DNA of the sample to be tested is > 35 or No Ct, the result is invalid;
[0079] If the HEX channel Ct value of the negative control product is ≤35, other channels display No Ct; the HEX channel Ct value of the positive control product is ≤35, and the FAM, ROX, and CY5 channel Ct values are <30; the FAM channel Ct value of the DNA of the sample to be tested is ≤38, TTV is determined to be positive;
[0080] If the HEX channel Ct value of the negative control product is ≤35, other channels display No Ct; the HEX channel Ct value of the positive control product is ≤35, and the FAM, ROX, and CY5 channel Ct values are <30; the ROX channel Ct value of the DNA of the sample to be tested is ≤38, TTMV is determined to be positive;
[0081] If the HEX channel Ct value of the negative control product is ≤35, other channels display No Ct; the HEX channel Ct value of the positive control product is ≤35, and the FAM, ROX, and CY5 channel Ct values are <30; the CY5 channel Ct value of the DNA of the sample to be tested is ≤38, TTMDV is determined to be positive.
[0082] The present invention includes but is not limited to the following beneficial effects:
[0083] (1) The present invention designs specific primer probes for gene conservative sequences, and the amplification reagent has excellent performance, has the advantages of high specificity and high sensitivity, and can realize the separate identification and typing identification of TTV, TTMV, and TTMDV.
[0084] (2) The amplification reagent of the present invention can be stored for a long time at 2-8°C, avoiding repeated freezing and thawing during use, making it more convenient for users to use.
[0085] (3) The non-frozen amplification reagents of the present invention can be used in real time with a fully automatic nucleic acid purification and real-time fluorescence PCR analysis system. After being put on the machine, one can wait for the results, which greatly reduces the number of manual operation steps.
[0086] In summary, the present invention has high sensitivity, high specificity, and low time consumption, and provides an efficient solution for the in vitro qualitative identification of human parvoviruses TTV, TTMV, and TTMDV, which has important clinical significance. BRIEF DESCRIPTION OF THE DRAWINGS
[0087] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.
[0088] Figure 1 Shows TTV amplification diagram;
[0089] Figure 2 Shows TTMV amplification diagram;
[0090] Figure 3 Shows the TTMDV amplification diagram;
[0091] Figure 4 Shows the mixed amplification diagram of TTV, TTMV and TTMDV. DETAILED DESCRIPTION
[0092] The present invention discloses a primer-probe combination for detecting human parvovirus and its application. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly pointed out that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The method and application of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0093] In view of the current shortcomings, the present invention provides a detection marker and a detection reagent for detecting human parvovirus TTV, TTMV and TTMDV, which can quickly and easily identify TTV, TTMV and TTMDV. The present invention has the advantages of simple operation, high sensitivity and strong specificity. In this detection method, the selection of detection targets, the design of primers and probes, the combination of targets and the interpretation of positive are the key points of the detection reagent.
[0094] The present invention adopts real-time fluorescence quantitative PCR method to make up for the shortcomings of existing methods, and has the advantages of high sensitivity, good specificity, and fast detection speed. This method is a one-step, completely closed-tube detection, eliminating the steps of running gels to judge the PCR products, and real-time quantitative examination of pathogenic genes. The result judgment is completed by a computer, which simplifies the operation and enhances the reliability of the results. Multiple real-time fluorescence quantitative PCR can simultaneously amplify multiple target genes in one tube reaction and quickly detect these genes at the same time.
[0095] The present invention selects conservative regions of human tenovirus TTV, TTMV and TTMDV genes to design primer probes, and each target gene sequence is used as a marker in the preparation of a detection reagent.
[0096] The experimental results show that using the conserved sequences of human parvovirus genes as detection markers can specifically detect and distinguish TTV, TTMV and TTMDV.
[0097] The present invention also provides a primer-probe combination for identifying TTV, comprising: two primers of the nucleotide sequences shown in SEQ ID NO.1-2, and a probe of the nucleotide sequence shown in SEQ ID NO.3.
[0098] The present invention provides a primer-probe combination for identifying TTMV, comprising: two primers of nucleotide sequences shown in SEQ ID NO.4-5, and a probe of nucleotide sequence shown in SEQ ID NO.6.
[0099] The present invention provides a primer-probe combination for identifying TTMDV, comprising: three primers of nucleotide sequences shown in SEQ ID NOs. 7 to 9, and a probe of the nucleotide sequence shown in SEQ ID NO.10.
[0100] The kit of the present invention also includes a primer-probe combination for detecting a human internal reference, wherein the internal reference is the β-globin gene, and the nucleotide sequences of the primers are shown in SEQ ID NOs.11-12; and the nucleotide sequence of the probe is shown in SEQ ID NO.13.
[0101] Specifically, the PCR reaction solution 1 and PCR reaction solution 2 in the kit;
[0102] The PCR reaction solution 1 comprises a PCR reaction buffer, 50 pmol Tris-HCL (pH 7.9-8.8), 100 pmol KCL, 2% Glycerol, 0.2 mmol dNTP, 2 U bifunctional DNA polymerase, 0.1-0.5 μmol (SEQ ID NO.1-2, SEQ ID NO.4-5, SEQ ID NO.7-9, SEQ ID NO.11-12) of 9 primers of nucleotide sequences, and 0.05-0.2 μmol (SEQ ID NO.3, SEQ ID NO.6, SEQ ID NO.10, SEQ ID NO.13) of 4 probes of nucleotide sequences;
[0103] The PCR reaction solution 2 contains 2 mmol Mn(CH3COO)2.
[0104] In the kit provided by the present invention, the PCR reaction solutions 1 and 2 have stable performance and can be stored for 12 months at 2-8°C, thus avoiding repeated freezing and thawing that affects the performance of the reagents. The experimental results show that the kit provided by the present invention still has good detection performance after being accelerated at 37°C for 21 days.
[0105] In the kit as described above,
[0106] The 5' end of the probe of the nucleic acid sequence shown in SEQ ID NO.3 is modified with a FAM group, and the 3' end is modified with a BHQ1 group;
[0107] The 5' end of the probe of the nucleic acid sequence shown in SEQ ID NO.6 is modified with a ROX group, and the 3' end is modified with a BHQ2 group;
[0108] The 5' end of the probe of the nucleic acid sequence shown in SEQ ID NO.10 is modified with a CY5 group, and the 3' end is modified with a BHQ3 group;
[0109] The 5' end of the probe of the nucleic acid sequence shown in SEQ ID NO. 13 is modified with a HEX group, and the 3' end is modified with a BHQ1 group.
[0110] In the method described above, preferably, the amplification system includes: 115 μl of PCR reaction solution, 215 μl of PCR reaction solution, and 20 μl of nucleic acid of the sample to be tested.
[0111] In the method described above, preferably, the amplification program includes: 50°C for 2 min, 95°C for 2 min, (95°C for 10 s, 60°C for 22 s, 45 cycles), 40°C for 10 s.
[0112] Quality control product judgment rules: negative quality control product HEX channel Ct value ≤35, FAM channel, ROX channel and Cy5 channel display No Ct; positive quality control product FAM channel Ct value ≤30; ROX channel Ct value ≤30; CY5 channel Ct value ≤30.
[0113] The present invention provides primers, probes and kits for identifying TTV, TTMV and TTMDV. The kit can rapidly identify human parvovirus in serum or plasma, has good sensitivity and accuracy, and can avoid interference of other types of common pathogens on the experimental results, providing a reliable experimental basis for the identification of human parvovirus.
[0114] Unless otherwise specified, the primer-probe combination for detecting human parvovirus provided by the present invention and the raw materials and reagents used in its application can all be purchased from the market.
[0115] The present invention will be further described below in conjunction with embodiments:
[0116] Example 1 Fluorescence PCR kit for identifying human parvoviruses TTV, TTMV and TTMDV
[0117] The fluorescent PCR kit for identifying human parvoviruses TTV, TTMV and TTMDV specifically includes the following components:
[0118] PCR reaction solution 1: The basic solution is 50 pmol Tris-HCl (pH 8.3), a total of 15 μl, including 0.2 μmol primer, 0.1 μmol probe, 100 pmol KCL, 2% Glycerol, 0.2 mmol dNTP, and 2 U bifunctional DNA polymerase.
[0119] The primers are:
[0120] Primer 1: 5'-CCCTTGACTGCGGTGTGTAAAC-3' (SEQ ID NO. 1);
[0121] Primer 2: 5'-GTTTTCCACGCCCGTCC-3' (SEQ ID NO. 2);
[0122] Primer 3: 5′-CAAGAGGCGTGTCTWATGTGCT-3′ (SEQ ID NO. 4);
[0123] Primer 4: 5'-CTAGCCCGAATTGCCCCT-3' (SEQ ID NO. 5);
[0124] Primer 5: 5'-CCTCGTTCCGACCCGCTT-3' (SEQ ID NO. 7);
[0125] Primer 6: 5′-CTCGGAGTCTGTTTAGTAAATAAGCG-3′ (SEQ ID NO. 8);
[0126] Primer 7: 5′-CTCGGAGTCTGTTTAGTAAGTAGCG-3′ (SEQ ID NO. 9);
[0127] Primer 8: 5′-GAAGGCTCATGGCAAGAAAG-3′ (SEQ ID NO. 11);
[0128] Primer 9: 5'-CTCACTCAGTGTGGCAAAGG-3' (SEQ ID NO. 12).
[0129] The probes are:
[0130] Probe 1: 5'-CGGCACCCGCCCTCGGGA-3' (SEQ ID NO. 3);
[0131] Probe 2: 5'-CTTGGGCGGGAGCCGAAGGTG-3' (SEQ ID NO. 6);
[0132] Probe 3: 5'-GTCGGACCACTWCGGGCTCGG-3' (SEQ ID NO. 10);
[0133] Probe 4: 5'-CTTGAGGTTGTCCAGGTGAGCCAG-3' (SEQ ID NO. 13).
[0134] PCR reaction solution 2: The base solution is H2O, a total of 15μl, including 2mmol Mn(CH3COO)2.
[0135] Negative quality control: The basic solution is TE, 1000μl, containing human β-globin gene plasmid at a concentration of 5.00E+05Copies / ml.
[0136] Positive quality control: The basic solution is TE, 1000μl, containing TTV plasmid at a concentration of 2.00E+05Copies / ml, TTMV plasmid at a concentration of 2.00E+05Copies / ml,
[0137] TTMDV plasmid at a concentration of 2.00E+05 copies / ml, and β-globin gene plasmid at a concentration of 5.00E+05 copies / ml.
[0138] Example 2 Identification of human parvoviruses TTV, TTMV and TTMDV
[0139] The fluorescent PCR kit prepared in Example 1 was used to identify human parvoviruses TTV, TTMV and TTMDV. The specific experimental method is as follows:
[0140] 1. Reagent preparation
[0141] According to the number of samples to be tested and positive and negative quality control products, taking 50μl total amplification volume as an example, prepare the corresponding amount of reaction solution (115μl PCR reaction solution per person, 215μl PCR reaction solution per person). If the total amount is N, prepare N+1 PCR reaction solutions, mix them and set aside.
[0142] 2. Template extraction
[0143] The nucleic acid extraction and purification kit (Antu Biotechnology, Yuzheng Xiebei No. 20180037) was followed to obtain the template for subsequent polymerase chain reaction.
[0144] 3. Polymerase chain reaction
[0145] Prepare the reaction system in a 100 μl PCR tube: 30 μl PCR reaction mixture, 20 μl template, and perform amplification detection on a real-time fluorescence PCR system. The amplification program is: 50°C for 2 min, 95°C for 2 min, (95°C for 10 s, 60°C for 22 s, 45 cycles), 40°C for 10 s.
[0146] 4. Result judgment
[0147] The amplification diagrams of TTV, TTMV and TTMDV are shown in Figures 1 to 3 As shown, the 3 targets were gradiently amplified artificially synthesized plasmid samples, and the sample concentrations were 4.00E+05Copies / ml, 2.00E+04Copies / ml, and 1.00E+03Copies / ml. The negative quality control HEX channel showed a Ct value of ≤35, and the other channels showed No Ct; the three channel values of the positive quality control should all be less than 30. In the above case, the results of the samples to be tested are explained as follows:
[0148] Table 1 Results interpretation
[0149]
[0150] 5. Verification
[0151] Artificially synthesized human parvovirus TTV, TTMV and TTMDV samples were taken and diluted to 4.00E+05Copies / ml, 2.00E+04Copies / ml, 1.00E+03Copies / ml and 1.00E+02Copies / ml respectively as test samples for amplification detection. The results are shown in Table 2.
[0152] Table 2 Verification results
[0153]
[0154] Conclusion: The fluorescent PCR kit prepared in Example 1 detected human cycloviruses at concentrations of 4.00E+05Copies / ml, 2.00E+04Copies / ml, 1.00E+03Copies / ml, and 1.00E+02Copies / ml, and the human cycloviruses TTV, TTMV, and TTMDV were all positive. The fluorescent PCR kit prepared in Example 1 can be used for the identification of human cycloviruses TTV, TTMV, and TTMDV.
[0155] Example 3 Sensitivity Test
[0156] According to the identification method described in Example 2, 10 samples with a concentration of 100 copies / ml were tested, and the data are shown in Table 3.
[0157] Table 3 Detection limit verification results
[0158] Detection target TTV TTMV TTMDV Sample No. FAMCt ROX Cy5Ct 1 34.6 35.78 34.87 2 35.03 35.63 35.03 3 35.01 36.33 34.22 4 34.16 35.25 34.85 5 34.98 34.94 34.08 6 36.19 34.56 34.82 7 35.01 35.22 34.23 8 36.01 34.22 34.8 9 36.2 35.73 34.65 10 35.43 35.94 35.69
[0159] Conclusion: This kit was used to test 10 positive samples (100 Copies / ml), and the results were all positive, proving that the detection limit of the kit is no more than 100 Copies / ml.
[0160] Example 4 Specificity Test
[0161] Pathogens that may cross-react with human parvovirus and human genome were detected according to the identification method described in Example 2, and the results obtained are shown in Table 4.
[0162] Table 4 Specificity test results
[0163]
[0164]
[0165] Conclusion: This kit has no cross reaction to porcine parvovirus, canine parvovirus, feline parvovirus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, hepatitis A virus, hepatitis B virus, hepatitis C virus, porcine circovirus, human parvovirus B19, human genome, etc.
[0166] Example 5 Stability Test
[0167] Artificially synthesized human parvovirus samples were taken and diluted to 4.00E+05Copies / ml, 2.00E+04Copies / ml, 1.00E+03Copies / ml, and 1.00E+02Copies / ml, respectively. The prepared reagents were placed in a 37°C constant temperature incubator for accelerated stability verification. The test results were compared with the results of the 0-day test according to the identification method described in Example 2. If the result deviation did not exceed ±1.5 Ct, the test results could be judged to be indifferent, i.e., they met the requirements. The results are shown in Table 5.
[0168] Table 5 Stability test results
[0169]
[0170]
[0171] Conclusion: After 21 days of accelerated testing, the Ct value difference between the test results and those on day 0 was within 1, indicating that the reagent has excellent accelerated stability. When stored at 2-8°C, the reagent has a shelf life of more than 12 months.
[0172] Example 6 Identification of human parvoviruses TTV, TTMV and TTMDV
[0173] According to Table 6, the PCR reaction solution was prepared, and the primers and probes described in Example 1 were used to detect human cyclovirus TTV, TTMV and TTMDV using the method described in Example 2. The test results are shown in Table 7. Schemes 1-4 did not produce any value when detecting the human genome, and the results were normal; Schemes 1 and 2 detected the detection limit samples of three human cycloviruses (1.00E+02Copies / ml), which was lower than Scheme 3-CT, but could be detected normally, and there was no significant difference between Scheme 4 and Scheme 3.
[0174] Table 6 PCR reaction solution
[0175] Solution 1 Solution 2 Solution 3 Solution 4 Tris-HCl / pmol 30 50 50 70 KCl / pmol 80 100 100 120 Glycerol / % 1% 2% 2% 3% dNTP / mmol 0.2 0.1 0.2 0.3 Bifunctional DNA polymerase / U 2 1 2 3 Primer / μmol 0.3 0.1 0.3 0.5 Probe / μmol 0.1 0.05 0.1 0.2 <![CDATA[Mn(CH3COO)2 / mmol]]> 2 1 2 3
[0176] Table 7 Detection results of human parvovirus TTV, TTMV and TTMDV
[0177]
[0178]
[0179] Primer probe screening
[0180] In the preliminary experimental stage of the present invention, a large number of primer-probe combinations were screened, and multiple pairs of primer-probe combinations were designed in the conserved region of the gene. Artificially synthesized plasmids (with concentrations of 2.00E+04Copies / ml, 2.00E+02Copies / ml, and 5.00E+01Copies / ml, respectively) were used for amplification to obtain the primer-probe combination with the best amplification effect.
[0181] Reaction system: (PCR reaction solution 1: PCR reaction buffer, 50 pmol Tris-HCL (PH8.3), 100 pmol KCL, 2% Glycerol, 0.2 mmol dNTP, 2 U bifunctional DNA polymerase, 0.375 primers, 0.125 μmol probe; PCR reaction solution 2: contains 2 mmol Mn (CH3COO)2).
[0182] The primer and probe sequences used in each group are shown in Table 8:
[0183] Table 8 Primer probe sequences
[0184]
[0185]
[0186] Reaction program: 50°C for 2 min, 95°C for 2 min, (95°C for 10 s, 60°C for 22 s, 45 cycles), 40°C for 10 s.
[0187] The test results are as follows:
[0188] Table 9 TTV primer probe screening
[0189]
[0190] Table 10 TTMV primer probe screening
[0191]
[0192] Table 11 TTMDV primer probe screening
[0193]
[0194]
[0195] The TTV results are shown in Table 9. The experimental group, i.e., the primer-probe combination of two primers with nucleotide sequences shown in SEQ ID NO.1-2 and a probe with a nucleotide sequence shown in SEQ ID NO.3, has the best amplification performance; the TTMV results are shown in Table 10. The experimental group, i.e., the primer-probe combination of two primers with nucleotide sequences shown in SEQ ID NO.4-5 and a probe with a nucleotide sequence shown in SEQ ID NO.6, has the best amplification performance; the TTMDV results are shown in Table 11. The experimental group, i.e., the primer-probe combination of three primers with nucleotide sequences shown in SEQID NO.7-9 and a probe with a nucleotide sequence shown in SEQ ID NO.10, has the best amplification performance.
[0196] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A primer-probe combination for detecting human parvovirus, characterized in that: Include any of the following: (I), a first primer pair for specifically amplifying the 5'UTR gene of TTV; and a first probe for detecting the amplification product of the first primer pair; (II), a second primer pair for specifically amplifying the 5'UTR gene of TTMV; and a second probe for detecting the amplification product of the second primer pair; (III), a third primer pair for specifically amplifying the ORF1 gene of TTMDV; and a third probe for detecting the amplification product of the third primer pair.
2. The primer-probe combination according to claim 1, characterized in that: The primer-probe combination comprises: (I), a specific primer pair having the nucleotide sequences shown in SEQ ID NO.1 and SEQ ID NO.2; A probe having a nucleotide sequence as shown in SEQ ID NO.3; and / or (II), a specific primer pair having the nucleotide sequences shown in SEQ ID NO.4 and SEQ ID NO.5; A probe having a nucleotide sequence as shown in SEQ ID NO.6; and / or (III), a specific primer pair having a nucleotide sequence as shown in SEQ ID NO.7, SEQ ID NO.8 and SEQ ID NO.9; A probe having a nucleotide sequence as shown in SEQ ID NO.10; and / or (IV) a nucleotide sequence encoding the same protein as the nucleotide sequence shown in any one of (I) to (III) but different from the nucleotide sequence shown in any one of (I) to (III) due to the degeneracy of the genetic code; or (V) a nucleotide sequence obtained by replacing, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in any one of (I) to (IV), and a nucleotide sequence having the same or similar function as the nucleotide sequence shown in any one of (I) to (IV); or (VI) A nucleotide sequence having at least 90% sequence homology with the nucleotide sequence of any one of (I) to (V).
3. The primer-probe combination according to claim 1 or 2, characterized in that: The method also includes a primer pair and a probe for amplifying and detecting an internal reference gene, wherein the internal reference gene includes one or more of GAPDH, ribonuclease P, β-globin or Actin.
4. The primer-probe combination according to any one of claims 1 to 3, characterized in that: The probe includes a fluorescent group and a quenching group, wherein the fluorescent group includes FAM, VIC, ROX, CY5, and JOE; and the quenching group includes BHQ1, BHQ2, BHQ3, SQ1, and SQ2.
5. Use of the primer-probe combination according to any one of claims 1 to 4 in the preparation of a reagent or kit for detecting and / or identifying human parvovirus.
6. A combination reagent, characterized in that: The method comprises the primer-probe combination according to any one of claims 1 to 4.
7. A kit, characterized in that Including any of the following items and PCR reaction reagents: (I) a primer-probe combination as described in any one of claims 1 to 4; and / or (II) The combined reagent according to claim 6.
8. The kit according to claim 7, characterized in that The PCR reaction reagents include: dNTP, DNA polymerase, buffer, and enzyme activator; The buffer comprises one or more of Tris-HCl, KCL and glycerol.
9. The kit according to claim 7 or 8, characterized in that The PCR reaction procedure includes:
10. A method for identifying human parvoviruses TTV, TTMV and TTMDV, characterized in that: The steps include: Step 1, obtaining DNA of the sample to be tested; Step 2: Perform PCR amplification on the DNA of the sample to be tested using the kit described in any one of claims 7 to 9 to obtain a Ct value.
